SARASOTA, Fla., May 14, 2024
/PRNewswire/ -- Omeza®, a regenerative skincare company
that develops marine-based therapies for wounds that are hard to
treat, today announced a submission of an evaluation
of OCM™ Wound Matrix to a wound care journal under
the peer review process. The 3-case series included wounds (2 being
Medicare recipients), which were considered non-healing after more
than 3 months treatment of standard care. The prior standard of
care included debridement, offloading, compression bandages,
alginates, collagen, gelling hydrofibers and foam dressings.
All patients were treated with OCM™, a drug/device
containing cold water fish peptides and other pharmaceutical-grade
components that create an absorbable matrix which conforms to the
wound bed and supports the synthesis of new tissue. Patients were
seen weekly for wound evaluation and dressing changes. Wound
measurement and fluorescence imaging were conducted during visits
with a fluorescence imaging device (Moleculight i:X, Moleculight
Inc., Toronto CA).
Previous Medicare reports have confirmed that hard to heal
wounds have an estimated annual Medicare spend of $28.1 to $96.8
Billion. The longer a wound remains unhealed, the more costs
accumulate as does the risk for downstream complications (e.g.
infection, amputation).
In the case series, the mean area percent of reduction was 82%
upon completion, with 2 complete closures out of 3 cases. Complete
tissue negative fluorescence was achieved in the wound bed within 4
weeks.
The results of this case series also support in-vivo data from
the University of Miami, which
demonstrated significant antimicrobial decrease over controls in
Pseudomonas aeruginosa and MRSA infected wounds. These results are
being presented at the SAWC Conference in Orlando, Florida from May 14th-18th, 2024.
Dr. Desmond Bell, Chief Medical
Officer for Omeza states, "The results from this case series and
the University of Miami antimicrobial
studies adds to the growing evidence that supports the
effectiveness of OCM™ as a uniquely important modality
for the management of wounds, especially when addressing the
presence of significant bacterial burden that may contribute to
non-healing. OCM™ has not only demonstrated
the ability to reduce harmful bacteria, but unlike antibiotics and
topical chemicals, there is no risk of bacterial resistance
associated with the components of OCM™, and no risk of
cytotoxicity to newly developing cells needed for healing."
Studies to further evaluate the performance of OCM™
in patients with venous leg ulcers (VLUs) and in multiple wound
types have been completed, and are being prepared for submission to
peer review journals. Patient recruitment for a randomized clinical
trial in Venous leg ulcers will commence Q4 2024.
About OMEZA
Omeza® is a commercial-stage regenerative skin and
wound-care company that develops marine-based products comprising
containing cold water fish peptides and other pharmaceutical-grade
components designed to reduce inflammation, increase tissue
proliferation, and support skin remodeling in adults with a range
of hard to treat, non-healing wounds. Founded in 2014, the company
currently markets OCM™ for the treatment
of nonhealing wounds. OCM™ is also being evaluated
in real-world settings and in multiple clinical trials to compare
the effects of OCM™ versus standard of care on wound
healing, pain reduction, quality of life, and other secondary
endpoints in patients with diabetic ulcers, chronic venous leg
ulcers, and multiple other wound types. The company is
headquartered in Sarasota,
Florida, and has manufacturing, facilities located in
Florida.
Media Contacts:
Bernadette
Cupit
bcupit@omeza.com
908-334-4554
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novel-omeza-ocm-wound-matrix-demonstrates-multi-modal-effects-by-reducing-bacterial-contamination-in-stalled-hard-to-treat-wounds-while-supporting-healing-rates-302145007.html
SOURCE Omeza LLC